Circle Pharma, Inc. is excited to announce the successful completion of its latest fundraising round, securing a remarkable $607 million to fuel the advancement of its innovative macrocyclic peptide therapeutics. Founded in June 2014 with initial backing from industry giants like Pfizer, Inc. and Mission Bay Capital, LLC, Circle Pharma has quickly become a leader in designing cutting-edge therapeutics that tackle significant clinical challenges, particularly within the oncology space. This latest funding round, bolstered by support from The Column Group and NextTech Invest, will enable Circle Pharma to accelerate the development of its proprietary pipeline targeting critical intracellular protein-protein interactions that are pivotal in cancer progression.
Circle Pharma’s unique approach leverages a computational structure-based design methodology that fuses physics, chemistry, and biology to predict and enhance drug-like properties of macrocyclic compounds. The company’s proprietary algorithms facilitate the creation of vast, diverse virtual libraries of cell-permeable macrocyclic scaffolds, allowing for the strategic incorporation of natural and synthetic components to optimize therapeutic efficacy and delivery. With this newfound capital, Circle Pharma plans to expand its research capabilities, enhance collaboration with partners, and ultimately bring transformative therapeutic options to patients battling cancer. As the company works diligently to push the boundaries of what is possible with peptide therapeutics, it remains steadfast in its mission: to deliver next-generation treatments that may redefine the standard of care in oncology.
